La cadena de opciones muestra datos clave de las opciones de acciones de Aptorum Gr a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Aptorum Gr..

Aptorum Gr (NASDAQ:APM) Bolsa, Cadena de Opciones

Aptorum Gr

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group Ltd

apM Coin

MORIEN RESOURCES CORP ORD by Morien Resources Corp.

Morien Resources Corp

EAGLE GRAPHITE INC by Eagle Graphite Inc.

APM HUMAN SVCS INTL PTY by APM HUMAN SVCS INTL PTY LTD.

ApartmentLove Inc

ASPERMONT LTD by ASPERMONT LTD.

Amper SA

Aperam SA

Trust for Professional Managers ActivePassive Intermediate Municipal Bond ETF

<p>Stephens &amp; Co.  analyst Terry McEvoy   downgrades Stock Yards Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYBT#NASDAQ">SYBT</a>) from Overweight to Equal-Weight and raises the price target from $70 to $76.</p>


News

Downgrades

Price Target

Analyst Ratings

SYBT

Stephens & Co. Downgrades Stock Yards Bancorp to Equal-Weight, Raises Price Target to $76

<p>Stephens &amp; Co.  analyst Jeff Garro   initiates coverage on Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) with a Overweight rating and announces Price Target of $39.</p>


Initiation

Stephens & Co. Initiates Coverage On Simulations Plus with Overweight Rating, Announces Price Target of $39

<p><strong>Polymarket</strong> bettors appear skeptical about <strong>Dogecoin </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) reaching significant price milestones by December, with only a 6% chance assigned to Dogecoin hitting $1 and a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41945659/dogecoin-to-69-cents-or-1-benzinga-readers-predict-how-high-it-could-fly-by-end-of-2024#:~:text=Only%2018%25%20of%20readers%20think,one%2Dyear%20high%20of%20%240.4359.">10% chance for $0.90.</a></p>
<p><strong>What Happened: </strong>These odds reflect the market&#8217;s doubts, despite the recent surge in Dogecoin's value following Donald Trump's election and <strong>Elon Musk</strong>'s involvement with the newly established Department of Government Efficiency, dubbed &#8220;DOGE.&#8221;</p>
<p>Currently, the highest <a href="https://polymarket.com/event/what-price-will-dogecoin-hit-before-december?tid=1731690152725">chance </a>Polymarket assigns is a 59% probability for Dogecoin hitting $0.45 by the end of November, indicating tempered enthusiasm among investors.</p>
<p>The class-action lawsuit filed by a group of Dogecoin investors against Musk, accusing him of manipulating Dogecoin&#8217;s price in 2021, was <a href="https://www.reuters.com/legal/lawsuit-claiming-elon-musk-rigged-dogecoin-ends-2024-11-15/">dismissed</a> Friday, removing a legal overhang for the meme coin.</p>
<p>The investors argued Musk&#8217;s tweets and appearances, including on Saturday Night Live, artificially boosted Dogecoin's price, but a judge ultimately dismissed the claim as <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41951069/dogecoins-flat-inflation-is-a-feature-not-a-bug-says-elon-musk">"aspirational and puffery."</a></p>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure></p>
<p><strong>Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42011875/solana-ripple-litecoin-etfs-may-be-on-the-table-under-trump-administration-industry-experts-think">Solana, Ripple, Litecoin ETFs May Be On The Table Under Trump Administration, Industry Experts Say</a></strong></p>
<p>Meanwhile, Musk's public support of Dogecoin remains strong; he recently endorsed its fixed inflation model as "<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41951069/dogecoins-flat-inflation-is-a-feature-not-a-bug-says-elon-musk">a feature, not a bug</a>," positioning Dogecoin as a potentially stable currency.</p>
<p>Musk's ongoing advocacy has already led to substantial gains for Dogecoin post-election, with major players like Spirit Blockchain Capital also stepping in to build a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41947920/a-dogecoin-strategic-reserve-one-company-is-working-on-it">significant reserve of the coin</a>.</p>
<p><strong>What&#8217;s Next: </strong>With discussions on the future of digital assets set to continue at Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19, attention will be on how regulatory and institutional interest could further shape Dogecoin's trajectory.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42011697/bitcoin-hacker-sentenced-to-5-years-for-laundering-billions-in-crypto-theft">Bitcoin Hacker Sentenced To 5 Years For Laundering Billions In Crypto Theft</a></strong></li>
</ul>
<p><em>Image created using artificial intelligence with Midjourney.</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

Dogecoin To $1 Until December? Probably Not Happening, Polymarket Traders Say

<p>Ladenburg Thalmann  analyst Jeff Cohen   downgrades Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) from Buy to Neutral.</p>


BNGO

Ladenburg Thalmann Downgrades Bionano Genomics to Neutral

<p>Barclays  analyst Christine Cho   maintains SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) with a Underperform and lowers the price target from $17 to $7.</p>


SEDG

Barclays Maintains Underperform on SolarEdge Technologies, Lowers Price Target to $7

<p>TD Cowen  analyst Krish Sankar   maintains Kulicke &amp; Soffa Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLIC#NASDAQ">KLIC</a>) with a Hold and raises the price target from $45 to $50.</p>


KLIC

TD Cowen Maintains Hold on Kulicke & Soffa Indus, Raises Price Target to $50

WIIM

Cue Biopharma shares are trading lower. The company reported Q3 financial results.

<p>Jefferies  analyst Corey Tarlowe   maintains Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Buy and lowers the price target from $110 to $90.</p>


Jefferies Maintains Buy on Dollar Gen, Lowers Price Target to $90

<p>On Thursday, <strong>Tapestry, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) announced the termination of its merger agreement with <strong>Capri Holdings Limited</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>), citing <a target="_blank" href="https://www.benzinga.com/news/buybacks/24/11/41971497/tapestry-and-capri-call-off-8-5b-deal-amid-legal-hurdles" rel="noreferrer noopener">uncertainty in the legal process.</a></p>
<p>Following the termination of the merger agreement, Tapestry said it will redeem $6.1 billion in senior notes tied to the acquisition, paying 101% of their principal amount plus accrued interest, as per the Special Mandatory Redemption clause. Tapestry will also reimburse Capri $45 million for transaction-related expenses.</p>
<p>Here are the analysts&#8217; takes <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41550527/why-capri-holdings-stock-is-falling-today" rel="noreferrer noopener">on the&nbsp;termination news</a>:</p>
<p><strong>Telsey Advisory Group: </strong>Analyst Dana Telsey maintained the Market Perform rating on Capri Holdings, lowering <a target="_blank" href="https://www.benzinga.com/quote/CPRI/analyst-ratings" rel="noreferrer noopener">the price forecast to $23 from $26</a>. Considering the string of disappointing results over the past several quarters, the analyst trimmed the price forecast.</p>
<p>Per the analyst, the company saw some initial successes, but the campaigns didn&#8217;t connect well with its core customers. It raised price points too quickly. Additionally, the brand reduced its signature products and introduced too much fashion, leading to deeper promotions to drive sales.</p>
<p>However, for Tapestry, the analyst raised the price forecast to $67 from $58, <a target="_blank" href="https://www.benzinga.com/quote/TPR/analyst-ratings" rel="noreferrer noopener">with an Outperform rating</a>. Telsey is optimistic about earnings growth from the new buyback authorization and the company&#8217;s strong balance sheet.</p>
<p>The analyst sees no near-term acquisitions while focusing on improving Kate&#8217;s performance.</p>
<p>Meanwhile, the Coach brand remains resilient, with a 2% increase in constant currency last quarter, the analyst writes.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/24/11/42014985/matt-gaetz-to-be-confirmed-as-attorney-general-in-a-trump-administration-not-so-fast-polymarket-traders-say" rel="noreferrer noopener">Matt Gaetz To Be Confirmed As Attorney General In A Trump Administration? Not So Fast, Polymarket Traders Say</a></strong></p>
<p><strong>Guggenheim: </strong>Analyst Robert Drbul maintained a Neutral rating on Capri Holdings, citing the company&#8217;s deteriorating results over the past few years. The analyst pointed out &#8220;multiple missteps&#8221; by the company, including focus on younger consumers, rapid price increases, and reduced promotions.</p>
<p>Drbul also criticized the reduction of signature styles and overemphasis on &#8220;fashion&#8221; at Michael Kors. At Versace, the shift toward luxury/quality alienated the aspirational consumer by removing statement items. The analyst lowered FY25/FY26 EPS estimates to $1.50/$2.00, down from $1.85/$2.10. Per Drbul, Capri&#8217;s current low valuation could attract offers.</p>
<p>Drbul reiterated the Buy rating on Tapestry, raising the price forecast to $70 from $60. The analyst notes Tapestry will focus on strengthening Coach and Kate Spade, not pursuing acquisitions for now. With the Capri merger behind, Drbul sees value in Tapestry&#8217;s current portfolio.</p>
<p>The company is expected to benefit from pricing power in FY25 and may reach a 19% operating margin, with long-term potential to return to pre-COVID margins, driven by DTC growth and expansion in Asia, Drbul writes.</p>
<p><strong>JP Morgan: </strong>Analyst Matthew R. Boss reiterated the Neutral rating on Capri Holdings, with a price forecast of $15. The analyst projects FY25 EPS of $1.44, 17% below consensus, with a 14% year over year revenue decline and a 45bps gross margin contraction.&nbsp;</p>
<p>For the second half of 2025, the analyst projects revenues to be down 13% (an improvement from the first half&#8217;s -15%), gross margins to decrease by 10bps year over year (compared to the first half&#8217;s -80bps).</p>
<p>Capri Holdings&#8217; shift to a higher direct-to-consumer sales mix has boosted full-price selling, but also increased operating expenses, Boss writes. The analyst warns that with limited opportunities to cut SG&amp;A costs, this could be challenging amid a slowing top-line growth.</p>
<p><strong>Price Action</strong>: CPRI shares are trading higher by 1.80% to $20.89 at last check Friday, while TPR shares are trading lower by 0.98% to $57.26.</p>
<p><em>Image via Unsplash</em></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42011697/bitcoin-hacker-sentenced-to-5-years-for-laundering-billions-in-crypto-theft" target="_blank" rel="noreferrer noopener">Bitcoin Hacker Sentenced To 5 Years For Laundering Billions In Crypto Theft</a></strong></li>
</ul>


Analyst Color

Equities

Reiteration

Markets

Trading Ideas

General

CPRI

Tapestry Poised For Solid Growth After Capri Merger Termination, Analysts Cite Struggles And Missteps At Capri

<p>TD Cowen  analyst Krish Sankar   maintains Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Buy and lowers the price target from $250 to $230.</p>


AMAT

TD Cowen Maintains Buy on Applied Mat, Lowers Price Target to $230

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Morgan Stanley</strong>.</p>
<p>Looking at options history for Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) we detected 23 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 56% of the investors opened trades with bullish expectations and 26% with bearish.</p>
<p>From the overall spotted trades, 7 are puts, for a total amount of $332,437 and 16, calls, for a total amount of $1,219,604.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $95.0 to $185.0 for Morgan Stanley during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Morgan Stanley's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Morgan Stanley's significant trades, within a strike price range of $95.0 to $185.0, over the past month.</p>
<h3>Morgan Stanley Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731696369_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.4</td>
<td>$140.00</td>
<td>$340.0K</td>
<td>3.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$6.85</td>
<td>$5.15</td>
<td>$6.85</td>
<td>$185.00</td>
<td>$136.8K</td>
<td>0</td>
<td>200</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.25</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$130.00</td>
<td>$125.2K</td>
<td>6.4K</td>
<td>293</td>
</tr>
<tr>
<td>MS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$14.9</td>
<td>$14.6</td>
<td>$14.75</td>
<td>$140.00</td>
<td>$103.2K</td>
<td>224</td>
<td>75</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$18.1</td>
<td>$18.1</td>
<td>$18.1</td>
<td>$115.00</td>
<td>$85.0K</td>
<td>7.3K</td>
<td>47</td>
</tr>
</tbody>
</table>
</p>
<h3>About Morgan Stanley</h3>
<p>Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments with approximately 45% of net revenue from its institutional securities business, 45% from wealth management, and 10% from investment management. About 30% of its total revenue is from outside the Americas. The company had over $5 trillion of client assets as well as around 80,000 employees at the end of 2023.</p>
<p>In light of the recent options history for Morgan Stanley, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Morgan Stanley Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 3,092,834, with MS's price up by 0.76%, positioned at $133.44.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 62 days.</li>
</ul>
<h3>Professional Analyst Ratings for Morgan Stanley</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $128.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Goldman Sachs has decided to maintain their Neutral rating on Morgan Stanley, which currently sits at a price target of $121.<br />
&#x2A; An analyst from Jefferies persists with their Buy rating on Morgan Stanley, maintaining a target price of $135.<br />
&#x2A; An analyst from Barclays persists with their Overweight rating on Morgan Stanley, maintaining a target price of $135.<br />
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Underweight rating for Morgan Stanley, targeting a price of $107.<br />
&#x2A; An analyst from Wells Fargo upgraded its action to Equal-Weight with a price target of $142. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Morgan Stanley, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Spotlight on Morgan Stanley: Analyzing the Surge in Options Activity

<p>Investors with significant funds have taken a bullish position in Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>), a development that retail traders should be aware of.</p>
<p>This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in LDOS usually indicates foreknowledge of upcoming events.</p>
<p>Today, Benzinga's options scanner identified 8 options transactions for Leidos Holdings. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 50% being bullish and 50% bearish. Of all the options we discovered, 7 are puts, valued at $974,530, and there was a single call, worth $29,500.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $130.0 to $170.0 for Leidos Holdings during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Leidos Holdings's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Leidos Holdings's significant trades, within a strike price range of $130.0 to $170.0, over the past month.</p>
<h3>Leidos Holdings Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731696364_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>LDOS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.4</td>
<td>$4.8</td>
<td>$5.4</td>
<td>$155.00</td>
<td>$346.1K</td>
<td>0</td>
<td>1.0K</td>
</tr>
<tr>
<td>LDOS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$8.4</td>
<td>$7.0</td>
<td>$8.4</td>
<td>$130.00</td>
<td>$168.0K</td>
<td>1.5K</td>
<td>77</td>
</tr>
<tr>
<td>LDOS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$12.7</td>
<td>$11.9</td>
<td>$11.9</td>
<td>$165.00</td>
<td>$148.7K</td>
<td>127</td>
<td>133</td>
</tr>
<tr>
<td>LDOS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.5</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$155.00</td>
<td>$111.9K</td>
<td>0</td>
<td>232</td>
</tr>
<tr>
<td>LDOS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.1</td>
<td>$5.8</td>
<td>$7.6</td>
<td>$160.00</td>
<td>$96.5K</td>
<td>202</td>
<td>289</td>
</tr>
</tbody>
</table>
</p>
<h3>About Leidos Holdings</h3>
<p>Leidos Holdings Inc is a technology, engineering, and science company that provides services and solutions in the defense, intelligence, civil, and health markets, both domestically and internationally. Company customer includes the U.S. Department of Defense ("DoD"), the U.S. Intelligence Community, the U.S. Department of Homeland Security ("DHS"), the Federal Aviation Administration ("FAA"), the Department of Veterans Affairs ("VA"), and many other U.S. civilian, state and local government agencies, etc. The company is engaged in three reportable segments; Defense Solutions, Civil, and Health. Defense Solutions provides technologically latest services, solutions, and products to a broad customer base. It generates key revenue from Defense Solutions.</p>
<p>After a thorough review of the options trading surrounding Leidos Holdings, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Leidos Holdings Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 2,765,461, the LDOS's price is down by -5.9%, now at $158.06. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 88 days.</li>
</ul>
<h3>What Analysts Are Saying About Leidos Holdings</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $212.6.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from TD Cowen has decided to maintain their Buy rating on Leidos Holdings, which currently sits at a price target of $200.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Leidos Holdings with a target price of $210.<br />
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Leidos Holdings, which currently sits at a price target of $230.<br />
&#x2A; An analyst from Baird persists with their Outperform rating on Leidos Holdings, maintaining a target price of $218.<br />
&#x2A; An analyst from Truist Securities persists with their Buy rating on Leidos Holdings, maintaining a target price of $205. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Leidos Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


LDOS

Unpacking the Latest Options Trading Trends in Leidos Holdings

<p>High-rolling investors have positioned themselves bullish on NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in NN often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 13 options trades for NextNav. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 69% bullish and 23% bearish. Among all the options we identified, there was one put, amounting to $105,000, and 12 calls, totaling $504,800.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $3.0 to $17.0 for NextNav over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for NextNav's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of NextNav's whale activity within a strike price range from $3.0 to $17.0 in the last 30 days. </p>
<h3>NextNav Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731696359_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$11.4</td>
<td>$11.3</td>
<td>$11.4</td>
<td>$3.00</td>
<td>$125.4K</td>
<td>2.9K</td>
<td align="right">110</td>
</tr>
<tr>
<td>NN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$1.75</td>
<td>$1.7</td>
<td>$1.75</td>
<td>$15.00</td>
<td>$105.0K</td>
<td>26</td>
<td align="right">600</td>
</tr>
<tr>
<td>NN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$7.2</td>
<td>$6.7</td>
<td>$6.7</td>
<td>$17.00</td>
<td>$46.9K</td>
<td>566</td>
<td align="right">70</td>
</tr>
<tr>
<td>NN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$7.9</td>
<td>$6.7</td>
<td>$7.84</td>
<td>$15.00</td>
<td>$39.4K</td>
<td>1.7K</td>
<td align="right">310</td>
</tr>
<tr>
<td>NN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.2</td>
<td>$4.0</td>
<td>$4.1</td>
<td>$12.00</td>
<td>$39.3K</td>
<td>693</td>
<td align="right">98</td>
</tr>
</tbody>
</table>
</p>
<h3>About NextNav</h3>
<p>NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation and Timing services in the absence of GPS.</p>
<p>In light of the recent options history for NextNav, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of NextNav</h3>
<ul>
<li>Trading volume stands at 568,994, with NN's price up by 0.85%, positioned at $14.27.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 117 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest NextNav options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Unpacking the Latest Options Trading Trends in NextNav

<p>TD Cowen  analyst Lance Vitanza   maintains Inseego (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSG#NASDAQ">INSG</a>) with a Hold and lowers the price target from $20 to $16.</p>


INSG

TD Cowen Maintains Hold on Inseego, Lowers Price Target to $16

<p>Jefferies  analyst Corey Tarlowe   maintains BJ's Wholesale Club (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) with a Buy and raises the price target from $95 to $105.</p>


Jefferies Maintains Buy on BJ's Wholesale Club, Raises Price Target to $105

<p>TD Cowen  analyst Bryan Bergin   maintains Globant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) with a Buy and raises the price target from $230 to $240.</p>


GLOB

TD Cowen Maintains Buy on Globant, Raises Price Target to $240

<p>Jefferies  analyst Corey Tarlowe   maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Buy and raises the price target from $90 to $100.</p>


Jefferies Maintains Buy on Walmart, Raises Price Target to $100

ABAT

American Battery Technology shares are trading lower. The company reported Q1 financial results.

<p>TD Cowen  analyst Doug Creutz   maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Hold and raises the price target from $108 to $123.</p>


TD Cowen Maintains Hold on Walt Disney, Raises Price Target to $123

<p>Jefferies  analyst Samad Samana   maintains NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) with a Buy and lowers the price target from $230 to $215.</p>


NICE

Jefferies Maintains Buy on NICE, Lowers Price Target to $215

JAGX and GNPX among Health Care movers

XTIA, PSNL and LIDR among mid-day movers

Andean Precious Metals Corp (APM) has gained Wednesday morning, with the stock increasing 888.10% in pre-market trading to 8.3. APM's short-term technical score of 55 indicates that the stock has traded more bullishly over the last month than 55% of stocks on the market. In the Biotechnology industry, which ranks 100 out o

Andean Precious Metals Corp (APM) has risen 888.10% Wednesday In Premarket Trading

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The best <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> to buy are in companies that put a lot of resources into research and development, often with nothing to show for it for years. </p>



<p>Regulatory hurdles make finding biotech stocks to buy challenging if you don&rsquo;t have the patience to wait it out.</p>



<p>But when biotech companies win approval to sell and marketing a drug, the potential for profits can be off the charts. That&rsquo;s why it&rsquo;s a good idea to at least consider biotech, and whether they have a spot in your portfolio.</p>



<p>Biotech stocks represent companies involved in the research, development and commercialization of biological-based products that are designed to improve health. These companies can include pharmaceuticals, biotechnology, medical devices, and healthcare services.</p>



<p>While the industry is challenging because of the regulatory approval process and keen competition, biotech stocks do have some significant advantages. </p>



<p>For example, they are relatively immune to economic downturns. Even when the economy does poorly, people and insurance companies will spend money on monthly medications they need to improve their quality of life. </p>



<p>As the population ages, healthcare spending for pharmaceuticals and other medical products will continue to increase.</p>



<p>We&rsquo;re using the Portfolio Grader to find the best biotech stocks to buy in today&rsquo;s market. Each of these stocks gets top grades.</p>



<h2>Eli Lilly &amp; Co. (LLY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/lly_eli_lilly_1600-300x169.png" alt="Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals XI"><div>Source: Jonathan Weiss / Shutterstock.com</div></div><p>Weight loss drugs are one of the most popular trends in the biotech industry right now, with an estimated <a href="https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity">42% of the U.S. population</a> considered obese. That&rsquo;s why the first two companies on our list are top picks, both of them are soaring on the strength of their weight loss medications.</p>



<p>The U.S.-based company in this equation is <strong>Eli Lilly &amp; Co.</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/lly-stock-quote/"><strong>LLY</strong></a>), which markets its obesity drug under the name Zepbound. About 1 in 3 people who took the injectable drug at its highest dose (15 mg) report losing more than 58 pounds over a 72-week period.</p>



<p>The drug in Zepbound, tirzepatide, is also used in another highly successful Lilly product called Mounjaro, which is used to treat type 2 diabetes. Analysts believe that Zepbound can eventually be worth $25 billion a year in sales, and that Mounjaro sales could jump from $5.2 billion in 2023 to $16 billion in 2024.</p>



<h2>Novo Nordisk (NVO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/nvo-stock-300x169.jpg" alt="Novo Nordisk logo on a corporate building"><div>Source: joreks / Shutterstock.com</div></div><p>The European entry into this equation is <strong>Novo Nordisk</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/"><strong>NVO</strong></a>), which has an injectable weight loss drug of its own called Wegovy. Wegovy was approved in 2021 in the U.S. to treat obesity and recently expanded to the U.K.</p>



<p>Expansion came with some growing pains, though. Some pharmacies continue to report shortages, and Novo Nordisk <a href="https://www.novonordisk-us.com/supply-update.html">says</a> its running its manufacturing lines 24 hours a day to try to maintain the supply.</p>



<p>Norvo Nordisk also manufactures the drug Ozempic as a treatment for type 2 diabetes, but doctors have also prescribed it as a treatment for weight loss.</p>



<p>NVO saw <a href="https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=167013">revenue</a> of $21.4 billion in the fourth quarter, up 31% from the previous year. Profits of $7.7 billion were a 51% increase from the previous year.</p>



<p>NVO stock is up 20% in 2024 and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Corbus Pharmaceuticals (CRBP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/crbp1600-300x169.png" alt="Corbus Pharmaceuticals (CRBP) leads in developing innovative drugs to treat inflammatory and fibrotic diseases. Exceptional quality patient focus"><div>Source: MacroEcon / Shutterstock.com</div></div><p><strong>Corbus Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/crbp-stock-quote/"><strong>CRBP</strong></a>) is a Massachusetts-based drugmaker specializing in oncology treatments. The company has potential drugs in its pipeline to treat solid tumors with antibody drug conjugates and monoclonal antibodies.</p>



<p>The most advanced treatment is treating U.S. patients with metastatic urothelial cancer <a href="https://www.corbuspharma.com/press-releases/detail/410/corbus-announces-dosing-of-first-patient-in-u-s-phase-1">in a trial study</a>.</p>



<p>Corbus also started work on a treatment for obesity and related conditions, although trials for that aren&rsquo;t expected to begin until the fourth quarter of this year.</p>



<p>Corbus doesn&rsquo;t have revenue coming in yet, so it&rsquo;s seeing steep losses &ndash; $8 million in the fourth quarter and $44.6 million for the full year. But that&rsquo;s expected for a biotech stock that has drugs in the pipeline but none yet for sale. You have to be willing to ride it out.</p>



<p>Many investors are. CRBP stock is up more than 500% so far this year as the market reacts to positive developments in the company&rsquo;s clinical trials. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Aptorum Group (APM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/apm-stock-1-300x169.jpg" alt="A magnifying glass zooms in on the website for Aptorum Group (APM)."><div>Source: Pavel Kapysh / Shutterstock.com</div></div><p><strong>Aptorum Group</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/apm-stock-quote/"><strong>APM</strong></a>) is a U.K.-based pharmaceutical company developing oncology and infectious diseases treatments. </p>



<p>Its approach includes screening approved drug molecules and using its research platform to seek and develop new treatments and therapies.</p>



<p>The company recently agreed to a <a href="https://www.marketwatch.com/story/aptorum-group-to-merge-with-yoov-group-split-off-legacy-assets-28822b75">reverse merger</a> between its wholly owned subsidiary and <strong>YOOV Group</strong>, specializing in AI techniques to optimize business operations. &nbsp;APM shareholders will own 10% of the combined company after the merger.</p>



<p>Aptorum also plans to split off its legacy business assets into a subsidiary to be called Aptorum Therapeutics.</p>



<p>News of the merger and restructuring turbocharged APM shares, which are now up 264% in 2024. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Merck &amp; Co. (MRK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/mrk-stock-3-300x169.jpg" alt="Merck (MRK) logo outside of corporate building"><div>Source: Atmosphere1 / Shutterstock.com</div></div><p><strong>Merck &amp; Co.</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/mrk-stock-quote/"><strong>MRK</strong></a>) is a New Jersey-based pharmaceutical company best known for its Keytruda cancer treatment. Keytruda brought in <a href="https://www.fiercepharma.com/pharma/whos-no-1-25b-sales-mercks-keytruda-appears-set-be-top-selling-drug-2023">$25 billion</a> in sales in 2023, making it the top-selling drug in the world.</p>



<p>But Merck also has many other drugs on the market, including Gardasil for human papillomavirus; ProQuad, which is a vaccine for measles, mumps, rubella and chickenpox; and Januvia for type 2 diabetes. And that&rsquo;s important, as Merck will lose exclusivity for Keytruda in 2028, making it available for generic substitutes.</p>



<p>Merck expanded that pipeline last month by <a href="https://www.merck.com/news/merck-completes-acquisition-of-harpoon-therapeutics-inc/">completing its acquisition</a> of Harpoon Therapeutics. The company&rsquo;s lead drug candidate treats small cell lung cancer and neuroendocrine tumors.</p>



<p>Earnings for the <a href="https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2023-financial-results/">fourth quarter</a> included revenue of $14.6 billion, up 6% from a year ago. The company reported a loss of $1.2 billion and 48 cents per share as part of previously announced charges incurred in its deal with <strong>Daiichi Sankyo</strong> to jointly develop three cancer treatments.</p>



<p>MRK stock is up 16% in 2024 and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Gyre Therapeutics (GYRE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p><strong>Gyre Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/gyre-stock-quote/"><strong>GYRE</strong></a>) is a North Carolina-based biotech company developing treatments for organ fibrosis and inflammatory diseases. </p>



<p>The company completed a Phase 2 trial in China for its treatment of hepatitis B-induced liver fibrosis.</p>



<p>It&rsquo;s now planning a Phase 2 trial for the treatment in the U.S. The drug candidate, Hydronidone, is a structural analog of pirfenidone, which is already approved in the U.S. and China for the treatment of idiopathic pulmonary fibrosis.</p>



<p>The company says there are more than 140 million people who have liver fibrosis from hepatitis B, with no approved therapies on the market. So, its treatment has the potential to be profitable for investors.</p>



<p>Gyre posted full-year revenue in 2023 of $113.5 million, up from $102.3 million in 2022.</p>



<p>GYRE stock is up 330% in the last 12 months, but has been falling so far in 2024. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Neurogene (NGNE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/bio1600-300x169.jpg" alt="MRNA Stock Will Continue Its Slump, but a $25 It Will Be a Great Buy"><div>Source: Shutterstock</div></div><p><strong>Neurogene</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ngne-stock-quote/"><strong>NGNE</strong></a>) is a biotech company that is developing what it calls EXACT gene therapy technology. </p>



<p>The platform can be used to achieve optimized levels of transgene expression for each drug candidate, which Neurogene says gives it an advantage over traditional gene therapy.</p>



<p>It&rsquo;s currently working with the platform to develop its lead gene therapy candidate for Rett syndrome, which is a disorder seen in children that impairs their ability to walk, eat, speak or breathe.</p>



<p>The company went public just last year in a <a href="https://ir.neurogene.com/news-releases/news-release-details/neurogene-announces-closing-merger-neoleukin-therapeutics-and">reverse merger</a> with cancer drug developer Neoleukin Therapeutics backed by investment firms that put $95 million into the newly formed company. The investment is expected to <a href="https://ir.neurogene.com/news-releases/news-release-details/neurogene-reports-fourth-quarter-and-full-year-2023-financial">assure Neurogene of funding</a> until the second half of 2026.</p>



<p>That gives it a solid window to develop and get approvals.</p>



<p>NGNE stock is up 95% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<p><em>On the date of publication, Louis Navellier held LLY and NVO. He did not have (either directly or indirectly) any other positions in the securities mentioned in this article.</em></p>



<p><em>The InvestorPlace Research Staff member primarily responsible for this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/market360/2024/04/7-a-rated-aggressive-biotech-stocks-to-bet-on-in-2024/">7 A-Rated Aggressive Biotech Stocks to Bet On in 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

CGC, GENE and HOLO among mid-day movers

Aptorum Group (APM) has released an update. Aptorum Group, a biopharmaceutical company, has reported a decreased net loss of $4.3 million for the f...

Aptorum Group Reports Decreased Annual Loss

Aptorum Group reports FY results

Aptorum Group (APM) has released an update. Aptorum Group Limited has announced an amendment to extend the term of its Merger Agreement with YOOV G...

Aptorum Group Extends Merger Agreement Term

Aptorum Group (APM) has released an update. Aptorum Group Limited announced the resignation of two directors, Dr. Mirko Scherer and Mr. Charles Bat...

Aptorum Group Board Sees Key Resignations

Aptorum Group (APM) has released an update. Aptorum Group has scheduled its 2024 Annual General Meeting for December 10 in Hong Kong, where shareho...

Aptorum Group Announces Key Shareholder Meeting

AILE

AISP

ALRN

ANGH

ANVS

APAC

AQST

BNTC

BPTH

CRBP

EDBL

FEMY

GENE

GNPX

GYRE

HOLO

ICLK

INLX

JAGX

LFCR

LIDR

MIGI

NGNE

NRXP

PSNL

RETO

RLMD

SINT

SWVL

TFFP

THCH

TOON

TRUG

TSHA

WISA

WORX

WULF

XPON

XTIA

XTLB

Press Releases

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

Comments

Aptorum Gr

Aptorum Gr (APM) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL